Document is current
Any future updates will be listed below
-
Authors
Simonato, Michele https://orcid.org/0000-0002-3586-2693
Agoston, Denes V.
Brooks-Kayal, Amy
Dulla, Chris https://orcid.org/0000-0002-6560-6535
Fureman, Brandy https://orcid.org/0000-0002-7862-4716
Henshall, David C. https://orcid.org/0000-0001-6237-9632
Pitkänen, Asla
Theodore, William H.
Twyman, Roy E. https://orcid.org/0000-0002-4208-6645
Kobeissy, Firas H. https://orcid.org/0000-0002-5008-6944
Wang, Kevin K.
Whittemore, Vicky
Wilcox, Karen S. https://orcid.org/0000-0003-2660-8826
- License Information
-
More Information
Article History
Accepted: 12 January 2021
First Online: 16 February 2021
Competing interest
: K.S.W. is on the scientific advisory board for and is shareholder of Blackfynn, and is a consultant for Xenon Pharmaceuticals. All other authors declare no competing interests.
